- Home
- MNY vs MIRA Comparison
MNY vs MIRA Comparison
Compare MNY & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MNY | MIRA |
|---|---|---|
| Founded | 2014 | 2020 |
| Country | Singapore | United States |
| Employees | 240 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.9M | 37.1M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | MNY | MIRA |
|---|---|---|
| Price | $0.97 | $0.88 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | 24.0K | ★ 50.5K |
| Earning Date | 04-30-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $19.58 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.78 | $0.83 |
| 52 Week High | $2.40 | $2.45 |
Technical Indicators
Market Signals| Indicator | MNY | MIRA |
|---|---|---|
| Relative Strength Index (RSI) | 43.76 | 39.00 |
| Support Level | $0.78 | N/A |
| Resistance Level | $1.03 | $1.02 |
| Average True Range (ATR) | 0.06 | 0.06 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 30.84 | 25.25 |
Price Performance
Historical ComparisonAbout MNY MoneyHero Limited
MoneyHero Ltd is a tech- and AI-powered personal finance aggregation and comparison platform and a digital insurance brokerage provider in Greater Southeast Asia. It operates in Singapore, Hong Kong, Taiwan and the Philippines. Its brand portfolio includes B2C platforms MoneyHero, SingSaver, Money101, Moneymax and Seedly, as well as the B2B platform Creatory. The company has four operating and reportable segments: Hong Kong, Singapore, the Philippines, and Taiwan. The Hong Kong segment generates the majority of the revenue.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.